The clinically important glycopeptide antibiotic vancomycin binds to bacterial cell wall peptides of Gram-positive bacteria which terminate in -Lys-D-Ala-D-Ala, thereby inhibiting cell wall synthesis resulting in cell death. Wehave removed the TV-terminal leucine residue of vancomycinby an Edman degradation and acylated the exposed amino group of residue 2 with JV-Me-Gly, A^-Me-D-Ala, acetyl, butyl, and isohexyl groups to generate novel vancomycin analogues. The binding of vancomycin and these vancomycin analogues to the bacterial cell wall analogue di-7V-Ac-L-Lys-D-Ala-D-Ala (DALAA) was studied by NMRtechniques and UVspectroscopy. The effects that these structural modifications of the carboxylate binding pocket of vancomycin have on the antibiotic-DALAA recognition process show that a cooperative effect between non-polar and ionic forces appears to be partly responsible for the highly efficient sequestering of the DALAAC-terminal carboxylate from aqueous solution.
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The recent discovery of bacterial strains resistant tc vancomycin, which is still the last line of defence ir combating the outbreaks of multiply-resistant staphylococci and enterococci in hospitals and clinics worldwide has greatly increased the interest in the vancomycir family of antibiotics. Wewish to elucidate the structura and thermodynamic factors which are responsible for the share a structural motif which is responsible for binding to the C-terminal carboxylate anion of the cell-wall peptide. This part of the cell wal binding pocket is essentially composed of a hydrophobicwalled cavity into which three of the backbone amide N-H bonds converge. In vancomycin (1) the hydrophobic walls of the cavity are formed by the side chain of residue 1 (iV-Me-D-leucine) and the non-polar portions of residues 2 and 3, while the amide N-H groups of these three residues form hydrogen bonds with the carboxylate of the cell wall peptide (Fig. 1) .2) Previous NMRstudies have identified interactions between the N-terminal amino acid of the antibiotic and cell wall which are thought to be favourable for binding.
The isobutyl side chain of the JV-Me-D-leucine residue of vancomycin was shown to fold in, and to bury part of a bound cell wall analogue in DMSO-d6solution.3~5) NOESY experiments showed also that the TV-terminal cationic amine plays a role in stabilizing the peptideantibiotic complex. The -+NH2CH3 of residue 1 is oriented such that the hydrophobic methyl group, and not the S+ N-H protons, is adjacent to the peptide carboxylate anion. This should thereby enhance the hydrophobic  surroundings of the carboxylate  binding  pocket;3~5) probably more significantly, the cationic charge has maximum exposure to the solvent. Due to the proximity of the amine to the carboxylate in the complex, some form of electrostatic stabilization also seems likely. This conclusion is supported by work of Feeney and co-workers who showed that upon deprotonation of the vancomycin TV-terminal amine in aqueous solution, complex formation with 7V-Ac-D-Ala-D-Ala becomes less favorable by S^kJmol"1 (a factor of ll in binding constant).6) We wished to investigate the roles of electrostatic stabilisation and hydrocarbon packing in the binding of cell wall analogues. Wereport here the synthesis of analogues of vancomycinin which the N-terminal residue of vancomycin has been modified to afford new vancomycin derivatives (Fig. 2) , and discuss the corresponding binding affinities of these compounds (Fig. 2) . After purification by reverse-phase HPLC,these compoundswere characterised by electrospray mass spectrometry and 2D NMR. In addition, the complexes of these analogues with DALAAwere studied by 2D NMR. The structural studies confirm that these analogues bind to the tripeptide in a manner similar to that for vancomycin itself, i.e., the NOEenhancement data are consistent with the binding picture illustrated in Fig.  1.3~5 and are shown in Table 2 . The first three entries of Table 2 allow an analysis of the effect of the stepwise removal of the isobutyl sidechain of vancomycin, while retaining the terminal -+NH2Me group. Removal of three of the four carbon atoms (and water exposure. Therefore the potential increase in binding constant due to this effect in isolation (taking the hydrophobic effect as lying in the range 0.20~0.23 kJmol"xA"2 at 298K9'1O) is a factor of 10-13, which is reasonably close to the factor of 19 above.
The effect of removing all 4 carbon atoms of the sidechain is a similar reduction in binding, in this case by a factor ofca. 20 (1 vs. 3, Table 2 ). We conclude that the enhancement of binding upon introduction of the D-Ala methyl group into the antibiotic (3 vs. 2) is small or negligible.
We now consider the relative binding affinities of vancomycin with those of compounds in which the -+NH2Me group has been removed, and the isobutyl sidechain is progressively removed ( Table 2, A consistent picture therefore emerges from these data: the main promotion of binding by a hydrocarbon group and a -+NH2Me group requires the presence of both. A number of factors maybe involved in this coopera- Thus, introduction of the -+NH2Me group in the absence of the -CH2CH(CH3)2 sidechain only slightly changes binding (cf. data for 3 and 6, in Table 1 ), whereas the same introduction in the presence of the -CH2CH(CH3)2 sidechain promotes binding by a factor of ca. 20 (cf. data for 1 and 4 in Table 2 ). The general conclusion is therefore clearbinding is cooperatively promoted by the -+NH2Meand -CH2CH(CH3)2 groups possibly through at least two effects: ( i ) the strengthening of the -CO^"---+NH2Me interaction in the presence of the -CH2CH(CH3)2 sidechain.
(ii) the strengthening of the hydrophobic effect in the presence of the positive charge of the -+NH2Me group.
The weaker binding seen in the complexes corresponding to rows 2~6 (Table 2) , relative to the corresponding vancomycin complex, is reflected in the difference in the chemical shift of the N-Hw2 proton of the antibiotics (AS), in the free and complexed state. For example, in free vancomycinat pH 4.5 and 1 mMconcentration, the w2 resonance (see Fig. 1 ) occurs at 8.79ppm. Addition of excess DALAA tripeptide (to ensure that formation of the complex is >95%) to the vancomycin solution causes the w2 resonance to shift down field to 1 1.69 ppm. This rather large AS value of 2.90ppm for vancomycin reflects the strong intermolecular hydrogen bond formed between the w2 and the DALAA carboxylate in the complex. For comparison, the AS values for the 2-, 3-, 4-, 5-, and 6-DALAA complexes are 1.90, 2.06, 2.05, 1.96, and 2.09 ppm respectively (available from the data presented in Table 3 ). Wetake the extent of the down field shift of the w2resonance as a measure of the strength AUG. 1995 points after a n/2 pulse. Recycle delays of between 1.5 and 2.0 seconds were employed. Carrier frequencies and spectral widths were adjusted to allow ca. 1 pprn either side of the observable resonances. In those cases where the residual HODsignal was intense, selective suppression was achieved by presaturation of the signal during the relaxation delay. All two dimensional experiments were recorded in phase-sensitive mode using time-proportional phase incrementation for quadrature detection in fx. The spectral widths used were the same as for the one dimensional experiments. Typically, either 32 or 64 transients of 2K data points each were recorded in the f2 dimension and 512 t± increments were recorded then zero-filled to 1 K data points. In cases where the residual water signal in deuterated solvent was intense, suppression was achieved by presaturation during the recycle delay. Prior to Fourier transformation, the spectra from double quantum filtered COSYexperiments were subjected to a phase-shifted sine bell weighting function in each dimension. The mixing time (tJ for phasesensitive NOESY spectra was set to 400ms, with a 20ms z-filter to reduce zero-quantumscalar coupling correlation by randomvariation of tm. Data sets were subjected to a Lorentz-Gaussian weighting function in both dimensions prior to Fourier transformation. UVspectra were recorded on a UVIKON 940 dual beam spectrophotometer at 303.2 + 0.1 K. Glycopeptide and ligand solutions were buffered with aqueous KH2PO4/NaOH (50mM/29mM) at pH 7.0. The initial concentration of glycopeptide used was 0.05 him. Four wavelengths were monitored during ligand binding titrations. These were chosen on the basis of a difference spectrum, determined with antibiotic in the reference cell, and antibiotic-ligand complex in the sample cell. This showed the wavelengths at which the UV spectra of antibiotic and antibiotic-ligand complex were most different. Two wavelengths at the apex of a peak due to a difference between antibiotic and complex (typically 293 and 294nm) and two wavelengths at the bottom of a valley due to a difference between antibiotic and complex (typically 283 and 284 nm) were chosen. Binding constants were determined by measuring the increase in the difference in absorption between the peak and the valley, with antibiotic solution in both the reference and sample beams. Ligand dissolved in the antibiotic solution was titrated into the cell in the sample beam (the ligand concentration used was in the range 5~30mM, depending on the magnitude of the binding constant to be measured). The solutions were stirred (20 seconds), left to settle (3 minutes) and the absorbances were then measured.The values for the absorbances at 293 and 294nmwere added together, and from this the sumof the absorbances at 283 and 284nmpairs of wavelengths was subtracted. The resulting data was fitted to the theoretical equation for 1 : 1 binding using least-squares methods.
Electrospray mass spectra were recorded on a VG 7V-/-Boc-7V-Me-D-Ala (56.9 mg, 0.28 nimbi) was dissolved in CH2C12 (1 ml) and cooled to 0°C. To this was added DCC (28.9mg, O.Hmmol) in CH2C12 (l ml) and the solution was stirred with cooling for 30 minutes and at room temperature for 30 minutes. After this time, a white precipitate which had formed was removed by filtration and discarded. A white solid was obtained from the supernatant after removal of the solvent under reduced pressure, and this was dissolved in DMF(2ml) A^-Boc-7V-Me-Gly-vancomycin N-t-Boc-N-Mc-Gly (143 mg, 0.76 mmol) was dissolved in dichloromethane (3ml).
To this was added DCC (78mg, 0.38mmol) as a solution in dichloromethane (3ml). After 1 hour at room temperature, the mixture was filtered to remove a white precipitate, which was discarded. A white solid was obtained from the supernatant after removal of the solvent under reduced pressure, and this was dissolved in DMF(5ml). Vancomycin hexapeptide (57 mg, 0.04 mmol).and NaHCO3
(anhydrous, 30mg, 0.36mmol) were added to this, and the reaction monitored by HPLC. After 2 hours, a single peak with longer retention time than the starting material was seen, and reaction was judged to be complete. The solvent was removed under reduced
